Abstract：
OBJECTIVE: To provide pooled analyses on the association between COVID-19 vaccine and the incidence of idiopathic sudden sensorineural hearing loss (ISSNHL).
METHODS: \"Medline\" via \"PubMed\", \"EMBASE\", and \"Google scholar\".
METHODS: Data sources were inspected from January 2020 to January 2024 using search terms relevant to vaccines for COVID-19. Included were papers with reported numbers of vaccinated populations and incidence if ISSNHL in those populations. Quality assessment was performed with the Newcastle-Ottawa Quality Assessment Scale Criteria.
RESULTS: Three publications encompassing more than 191.8 million patients and at least 283 million vaccine doses were included in the quantitative data synthesis. The pooled reported incidence (95%confidence interval) of ISSNHL among COVID-19 vaccine recipients was 1.2588 per 100,000 (0.1385-3.4836). This incidence is significantly lower than the incidence of 5-27 and 60 per 100,000/year reported in the United States and in the European Union, respectively (P < 0.0001).
CONCLUSIONS: There is no evidence to indicate that the COVID-19 vaccine is associated with the incidence of ISSNHL.
METHODS: \"Medline\" via \"PubMed\", \"EMBASE\", and \"Google scholar\".
METHODS: Data sources were inspected from January 2020 to January 2024 using search terms relevant to vaccines for COVID-19. Included were papers with reported numbers of vaccinated populations and incidence if ISSNHL in those populations. Quality assessment was performed with the Newcastle-Ottawa Quality Assessment Scale Criteria.
RESULTS: Three publications encompassing more than 191.8 million patients and at least 283 million vaccine doses were included in the quantitative data synthesis. The pooled reported incidence (95%confidence interval) of ISSNHL among COVID-19 vaccine recipients was 1.2588 per 100,000 (0.1385-3.4836). This incidence is significantly lower than the incidence of 5-27 and 60 per 100,000/year reported in the United States and in the European Union, respectively (P < 0.0001).
CONCLUSIONS: There is no evidence to indicate that the COVID-19 vaccine is associated with the incidence of ISSNHL.
摘要：
目的：对COVID-19疫苗与特发性突发性感音神经性耳聋（ISSNHL）发病率之间的关系进行汇总分析。
方法：\"Medline\"via\"PubMed\",\"EMBASE\",和“谷歌学者”。
方法：使用与COVID-19疫苗相关的搜索词，于2020年1月至2024年1月检查数据来源。包括报告的接种人群数量和这些人群中ISSNHL发生率的论文。使用纽卡斯尔-渥太华质量评估量表标准进行质量评估。
结果：三篇出版物涵盖了超过1.918亿患者和至少2.83亿剂疫苗剂量的定量数据合成。COVID-19疫苗接种者中ISSNHL的汇总报告发生率（95%置信区间）为1.2588/100,000（0.1385-3.4836）。这一发病率明显低于美国和欧盟报告的每100,000/年5-27和60的发病率，分别为(P<0.0001)。
结论：没有证据表明COVID-19疫苗与ISSNHL的发病率相关。
方法：\"Medline\"via\"PubMed\",\"EMBASE\",和“谷歌学者”。
方法：使用与COVID-19疫苗相关的搜索词，于2020年1月至2024年1月检查数据来源。包括报告的接种人群数量和这些人群中ISSNHL发生率的论文。使用纽卡斯尔-渥太华质量评估量表标准进行质量评估。
结果：三篇出版物涵盖了超过1.918亿患者和至少2.83亿剂疫苗剂量的定量数据合成。COVID-19疫苗接种者中ISSNHL的汇总报告发生率（95%置信区间）为1.2588/100,000（0.1385-3.4836）。这一发病率明显低于美国和欧盟报告的每100,000/年5-27和60的发病率，分别为(P<0.0001)。
结论：没有证据表明COVID-19疫苗与ISSNHL的发病率相关。
